CXCR2 and melanoma: Furthermore, BRAFi treatment-induced tolerance in melanoma could be shown to result from a cytokine-signaling network involving TAM-derived IL-1β and CAFs derived C-X-C motif chemokine receptor 2 (CXCR2) ligands.